Department of Urology, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan
Department of Urology, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
Anticancer Res. 2014 Jul;34(7):3781-7.
Sunitinib is known to cause a variety of adverse events. The aim of the present study was to investigate the prognostic significance of leukopenia for patients with advanced renal cell carcinoma (RCC) treated with sunitinib.
Between December 2008 and January 2012, 44 consecutive patients with advanced RCC were treated with sunitinib. Adverse events that occurred during the study were identified. Cox proportional hazards regression analysis estimated the relative importance of the predictive factors for progression-free survival (PFS).
On multivariate analysis, leukopenia was a significant predictor of PFS (p=0.0185). The cohort with leukopenia comprised of 36 patients (81.8%) and the cohort without leukopenia of 8 patients (18.2%). Patients with leukopenia had a significantly higher response rate (p=0.0062) and significantly longer PFS (p<0.0001) compared to patients without leukopenia.
Leukopenia is an independent, significant prognostic indicator for patients with advanced RCC treated with sunitinib.
舒尼替尼已知会引起多种不良反应。本研究旨在探讨白细胞减少对接受舒尼替尼治疗的晚期肾细胞癌（RCC）患者的预后意义。
2008 年 12 月至 2012 年 1 月，连续 44 例晚期 RCC 患者接受舒尼替尼治疗。本研究期间发生的不良反应。Cox 比例风险回归分析估计无进展生存期（PFS）预测因素的相对重要性。
多因素分析显示，白细胞减少是 PFS 的显著预测因素（p=0.0185）。白细胞减少组包括 36 例患者（81.8%），无白细胞减少组包括 8 例患者（18.2%）。白细胞减少组患者的客观缓解率明显更高（p=0.0062），无进展生存期明显更长（p<0.0001）。
白细胞减少是接受舒尼替尼治疗的晚期 RCC 患者的独立、显著预后指标。
